Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

Eli Lilly is the clear frontrunner to be the largest pharmaceutical stock in 2034. See what its prospects are for the next ...

Axial Spondyloarthritis (axSpA) is a form of arthritis that mainly causes discomfort and inflammation in the spine and ...

Two new papers by a team of researchers at Boston University, the Indiana University School of Medicine and the Alzheimer’s Disease Neuroimaging Initiative (ADNI), and the German Center for ...

Evercore ISI analyst Umer Raffat maintained a Buy rating on Organon (OGN – Research Report) today. The company’s shares opened ...

Real-world data showed reductions in healthcare resource utilization and improved glycemic control over 1 year with ...

MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in previously treated EGFR-mutated NSCLC.

Barron's market reporter Jacob Sonenshine breaks down the market as the Fed meeting kicks off and spotlights pharmaceutical company Merck.

Let’s take a look at the history of illegal and fraudulent dealings by players in the pharmaceutical industry; an industry that has way more power and influence than we give them credit for.

Metastatic solid tumors may be curable now. Among the most profound results presented over the weekend at the European ...

In the span of 30 minutes, 29-year Merck veteran Eliav Barr can analogize drug development dealmaking to Reese's candy, call himself an 'old fart' when asked about career plans, get real about the ...

Study findings support tivozanib monotherapy for second-line treatment of certain patients with metastatic RCC, an expert ...